Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has secured US Food and Drug Administration approval for two Ziihera, or zanidatamab-hrii, regimens in first-line HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal-junction and esophageal adenocarcinoma, moving the bispecific HER2 antibody from a previously treated biliary-cancer indication into a much larger frontline gastrointestinal oncology setting. FDA approved Ziihera with fluoropyrimidine- and platinum-containing chemotherapy plus BeOne Medicines’ Tevimbra, or tislelizumab-jsgr, in patients whose tumors are HER2 IHC 3+ or IHC 2+/ISH+, while Ziihera plus chemotherapy without Tevimbra was approved for the narrower HER2 IHC 3+ population. FDA simultaneously approved Roche/Ventana companion diagnostics for identifying patients according to those HER2 definitions.
The distinction between the two regimens reflects the evidence from HERIZON-GEA-01 rather than a simple choice of whether physicians prefer adding immunotherapy. In the three-drug biologic regimen, Ziihera plus tislelizumab and chemotherapy produced statistically significant gains in both progression-free survival and overall survival against trastuzumab plus chemotherapy. Median overall survival reached 26.4 months versus 19.2 months, corresponding to a hazard ratio of 0.72, while median progression-free survival improved to 12.4 months from 8.1 months with a hazard ratio of 0.63. Those results provide the strongest randomized evidence supporting the broader HER2-positive population, including IHC 2+/ISH+ disease.
Why does zanidatamab challenge the way HER2 has traditionally been targeted in gastric cancer?
Trastuzumab established HER2 as an actionable target in advanced gastric and gastroesophageal-junction cancer, but conventional trastuzumab binds a single HER2 extracellular domain. Zanidatamab is designed as a biparatopic antibody that recognizes two distinct HER2 epitopes simultaneously, allowing the same molecule to engage the receptor in a different configuration and potentially drive receptor clustering, internalization and immune-mediated antitumor activity more effectively than a conventional monospecific antibody.
That engineering difference matters because HER2 biology in gastroesophageal cancer is more heterogeneous than in many breast cancers. HER2 expression can vary substantially between areas of the same tumor and between primary and metastatic sites, while some cancers express high protein levels without uniform amplification across every malignant cell. A treatment capable of producing strong activity across a broader range of HER2 expression could therefore alter which patients benefit from first-line HER2 targeting.
The FDA label still draws an important biological line. Ziihera plus chemotherapy alone is approved in IHC 3+ disease rather than across the IHC 2+/ISH+ group because exploratory analyses indicated that the chemotherapy doublet’s benefit was driven mainly by tumors with the highest HER2 protein expression. In IHC 3+ patients, median PFS with Ziihera plus chemotherapy was 14.2 months compared with 7.6 months using trastuzumab plus chemotherapy, producing a hazard ratio of 0.55.
Why does adding tislelizumab broaden the eligible HER2 population?
The triplet regimen appears to combine two different forms of tumor selection. Zanidatamab attacks HER2-positive malignant cells directly, while tislelizumab blocks PD-1 signaling and attempts to restore antitumor T-cell activity. The randomized data suggest that this additional immune mechanism contributes enough incremental activity for FDA to authorize treatment not only in HER2 IHC 3+ cancers but also IHC 2+/ISH+ tumors.
Importantly, Jazz is positioning the triplet regardless of PD-L1 status. Earlier HER2-positive gastroesophageal treatment strategies often made immunotherapy decisions partly according to PD-L1 expression, but HERIZON-GEA-01 subgroup analyses have supported activity across PD-L1 categories. That could simplify treatment selection for HER2-positive patients if the combination becomes widely incorporated into clinical practice.
The approval nevertheless does not imply that HER2 or PD-L1 biology has become irrelevant. The FDA indication still requires HER2 confirmation with an authorized diagnostic, and the strength of the underlying HER2 signal affects which Ziihera regimen can be used.
How large was the HERIZON-GEA-01 comparison?
HERIZON-GEA-01 was a randomized, three-arm global trial comparing trastuzumab plus CAPOX or fluorouracil/platinum chemotherapy with Ziihera plus the same chemotherapy backbones and with Ziihera plus tislelizumab plus chemotherapy. This structure gave investigators a direct test of whether replacing trastuzumab with zanidatamab added benefit and whether adding PD-1 blockade to the new HER2 antibody created another incremental step.
The triplet produced the clearest survival result, cutting the relative risk of death by 28% and adding approximately 7.2 months to median overall survival at the reported analysis. In metastatic gastroesophageal cancer, where first-line treatment decisions influence both immediate disease control and the therapies a patient remains fit enough to receive later, that survival separation is clinically substantial.
The Ziihera-plus-chemotherapy arm presents a more nuanced picture. PFS was statistically superior to trastuzumab plus chemotherapy, but the interim overall-survival analysis had not reached statistical significance at the point supporting the current approval. FDA therefore narrowed that doublet indication to IHC 3+ disease, where exploratory evidence showed the most convincing treatment effect.
What safety liabilities accompany moving Ziihera into first-line treatment?
Ziihera’s prescribing information includes boxed warnings for severe diarrhea and embryo-fetal toxicity. Additional warnings include left-ventricular dysfunction and infusion-related reactions, concerns familiar from other HER2-directed therapies but still important when the antibody is combined with cytotoxic chemotherapy and, in one regimen, a checkpoint inhibitor.
Adding tislelizumab introduces immune-mediated toxicities associated with PD-1 blockade, including potential inflammatory injury affecting organs such as the lungs, liver, endocrine glands, skin and gastrointestinal tract. The clinical question therefore becomes whether the survival improvement justifies managing a more complex toxicity profile than HER2 antibody plus chemotherapy alone.
First-line therapy makes tolerability particularly important because patients may remain on treatment for prolonged periods and need to preserve sufficient fitness for subsequent options. Gastrointestinal toxicity also has greater practical consequence in patients whose underlying cancer can already interfere with eating, weight maintenance and nutritional status.
Why could the approval materially change Jazz Pharmaceuticals’ oncology business?
Ziihera generated $15 million in second-quarter 2026 sales from its existing biliary-tract cancer indication, illustrating that the product was still commercially small before the frontline GEA expansion. Gastroesophageal adenocarcinoma represents a much larger population, and Jazz estimates roughly one-fifth of cases show HER2-positive disease.
The company is also developing zanidatamab across biliary, breast and other HER2-expressing tumors, meaning first-line GEA provides both a significant revenue opportunity and a clinical validation of the biparatopic-antibody concept in a randomized head-to-head setting against trastuzumab.
Commercial adoption will depend partly on sequencing against other HER2-directed approaches and on how quickly treatment guidelines incorporate the new regimens. Physicians now have to decide not only whether to target HER2 but which HER2 platform to use and whether immunotherapy should accompany it from the first treatment cycle.
The August 25 approval therefore shifts the competitive baseline rather than simply adding another later-line option. Ziihera has moved into the point in the treatment pathway where the largest number of eligible patients are encountered, supported by a regimen that extended median survival beyond two years. The unresolved question is how rapidly that survival advantage converts trastuzumab-based first-line practice into zanidatamab-based practice across US oncology centers.
